

DAFTAR PUSTAKA

- Al-risi, E. S., & Al-essry, F. S. (2017). *Elham S. Al-Risi , Fatma S. Al-Essry 2 and Waad-Allah S. Mula-Abed 2 * 1 2*. 32(5), 365-370. <https://doi.org/10.5001/omj.2017.71>
- Amersi, F., Agustin, M., & Ko, C. Y. (2005). Colorectal cancer: Epidemiology, risk factors, and health services. *Clinics in Colon and Rectal Surgery*, 18(3), 133-140. <https://doi.org/10.1055/s-2005-916274>
- Costa, F., & Gumz, B. (2013). *Neuroendocrine Tumours Octreotide – A Review of its Use in Treating Neuroendocrine Tumours Neuroendocrine Tumours*. 105-109. <https://doi.org/10.17925/EOH.2013.09.2.105>
- Crabtree, J. S., & Miele, L. (2016). Neuroendocrine tumors: current therapies, notch signaling, and cancer stem cells. *Journal of Cancer Metastasis and Treatment*, 2(8), 279. <https://doi.org/10.20517/2394-4722.2016.30>
- D, Cui, J, Naftel, J. L. (2011). *Atlas of Histology with Functional and Clinical Correlations_ 9780781797597_ Medicine & Health Science Books @ Amazon*. LWW; Pap/Psc edition (August 3, 2010).
- DiFiore's. (2008). Atlas of Histology with functional correlations. In *Vasa*.
- Duan, K., & Mete, O. (2016). Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of

- immunohistochemical markers. *Cancer Cytopathology*, 124(12), 871-884. <https://doi.org/10.1002/cncy.21765>
- Fleming, M., Ravula, S., Tatishchev, S. F., & Wang, H. L. (2012). Colorectal carcinoma: Pathologic aspects. In *Journal of Gastrointestinal Oncology* (Vol. 3, Issue 3, pp. 153-173). <https://doi.org/10.3978/j.issn.2078-6891.2012.030>
- Frederick L, Greene C, A. G. F. (2013). *AJCC Cancer Staging Atlas_ Frederick L. Journal Of clinical Pathoogy.*
- Goldblum, J. R. (2018). Rosai and Ackerman's Surgical Pathology, 11th edition. In *Rosai and Ackerman's Surgical Pathology - 2 Volume Set* (pp. 648-670). <https://doi.org/10.1016/B978-0-323-26339-9.00041-X>
- Gudi, V., Gai, L., Herder, V., Tejedor, L. S., Kipp, M., Amor, S., Su, K., Hansmann, F., Beineke, A., Baumg, W., & Stangel, M. (2017). *Synaptophysin Is a Reliable Marker for Axonal Damage*. 76(2), 109-125. <https://doi.org/10.1093/jnen/nlw114>
- Gut, P., Czarnywojtek, A., Fischbach, J., Baczyk, M., Ziemnicka, K., Wrotkowska, E., Gryczyńska, M., & Ruchała, M. (2016). Chromogranin A - Unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. *Archives of Medical Science*, 12(1), 1-9. <https://doi.org/10.5114/aoms.2016.57577>
- Haggar, F. A., & Boushey, R. P. (2009). Colorectal cancer epidemiology: Incidence, mortality, survival, and risk factors. *Clinics in Colon and Rectal Surgery*, 22(4), 191-197. <https://doi.org/10.1055/s-0029->

1242458

- Hauso, O., Gustafsson, B. I., Kidd, M., Waldum, H. L., Drozdov, I., Chan, A. K. C., & Modlin, I. M. (2008). Neuroendocrine tumor epidemiology: Contrasting Norway and North America. *Cancer*, *113*(10), 2655-2664. <https://doi.org/10.1002/cncr.23883>
- Kalhan, A., & Rees, A. (2008). Neuroendocrine tumours. *Practical Clinical Oncology*, 418-425. <https://doi.org/10.1017/CBO9780511545375.037>
- Lawrence, B., Gustafsson, B. I., Chan, A., Svejda, B., Kidd, M., & Modlin, I. M. (2011). The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. *Endocrinology and Metabolism Clinics of North America*, *40*(1), 1-18. <https://doi.org/10.1016/j.ecl.2010.12.005>
- Lim, C. H., Lee, I. S., Jun, B. Y., Kim, J. S., Cho, Y. K., Park, J. M., Roh, S. Y., Lee, M. A., Kim, S. W., & Choi, M. G. (2017). Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: A single-center experience. *Korean Journal of Internal Medicine*, *32*(3), 452-458. <https://doi.org/10.3904/kjim.2015.232>
- Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018). Chromogranin a as circulating marker for diagnosis and management of neuroendocrine neoplasms: More flaws than fame. *Endocrine-Related Cancer*, *25*(1), R11-R29. <https://doi.org/10.1530/ERC-17-0269>
- Mescher, A. L. (2013a). *Junqueira's Basic Histology, Text and Atlas 13th Ed.* McGraw Hill Education.

- Mescher, A. L. (2013b). *Junqueira's Basic Histology: Text and Atlas, 15e* | *AccessMedicine* | McGraw-Hill Medical.
- Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010). Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. *Annals of Surgical Oncology*, 17(9), 2427-2443. <https://doi.org/10.1245/s10434-010-1006-3>
- NagArends MJ, Odze RD, L. Ak. I. (2019). *WHO GIT 2019.pdf* (pp. 158-191). WHO.
- Neuman, W. L., & Genta, R. M. (2013). *Cancer Grading Manual* (I. Damjanov & F. Fan (eds.); 2nd ed.). Springer US.
- Ni, S. J., Sheng, W. Q., & Du, X. (2010). Pathologic research update of colorectal neuroendocrine tumors. *World Journal of Gastroenterology*, 16(14), 1713-1719. <https://doi.org/10.3748/wjg.v16.i14.1713>
- Nölting, S., Kuttner, A., Lauseker, M., Vogeser, M., Haug, A., Herrmann, K. A., Hoffmann, J. N., Spitzweg, C., Göke, B., & Auernhammer, C. J. (2012). *Chromogranin A as Serum Marker for Gastroenteropancreatic Neuroendocrine Tumors: A Single Center Experience and Literature Review. February*, 141-155. <https://doi.org/10.3390/cancers4010141>
- Oberg, K., Couvelard, A., Delle Fave, G., Gross, D., Grossman, A., Jensen, R. T., Pape, U. F., Perren, A., Rindi, G., Ruzniewski, P., Scoazec, J. Y., Welin, S., Wiedenmann, B., & Ferone, D. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers. *Neuroendocrinology*,

105(3), 201-211. <https://doi.org/10.1159/000472254>

Oronsky, B., Ma, P. C., Morgensztern, D., & Carter, C. A. (2017). Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. *Neoplasia (United States)*, 19(12), 991-1002. <https://doi.org/10.1016/j.neo.2017.09.002>

Pertiwi, V. H., Hernowo, B. S., & Dewayani, B. M. (2019). *Imunoekspresi Chromogranin , Neuron Specific Enolase , Synaptophysin dan Ki-67 Pada Karsinoma Sel Skuamosa Yang Tidak Berkeratin dengan Pola Pertumbuhan Tumor Neuro- endokrin di Serviks Uteri*. 28(1).

Prestifilippo, A., Blanco, G., Paola, M., & Giuffri, D. (2012). Chromogranin A and Neuroendocrine Tumors. *Neuroendocrine Tumor*, 60(7), 386-395. <https://doi.org/10.5772/33357>

Shah, R., & Nalamati, S. P. M. (2015). Seminars in Colon and Rectal Surgery Neuroendocrine tumors of the colon and rectum. *Seminars in Colon and Rectal Surgery*, 26(2), 60-63. <https://doi.org/10.1053/j.scrs.2015.01.002>

Shinji, S., Naito, Z., Ishiwata, T., Tanaka, N., Furukawa, K., Suzuki, H., Seya, T., Kan, H., Tsuruta, H., Matsumoto, S., Matsuda, A., Teranishi, N., Ohaki, Y., & Tajiri, T. (2006). Neuroendocrine cell differentiation of poorly differentiated colorectal adenocarcinoma correlates with liver metastasis. *International Journal of Oncology*, 29(2), 357-364. <https://doi.org/10.3892/ijo.29.2.357>

Stewart, S. L., Wike, J. M., Kato, I., Lewis, D. R., & Michaud, F. (2006). A

- population-based study of colorectal cancer histology in the United States, 1998-2001. *Cancer*, 107(SUPPL.), 1128-1141. <https://doi.org/10.1002/cncr.22010>
- Taal, B. G., & Visser, O. (2004). Epidemiology of neuroendocrine tumours. *Neuroendocrinology*, 80(SUPPL. 1), 3-7. <https://doi.org/10.1159/000080731>
- Takizawa, N., Ohishi, Y., Hirahashi, M., Takahashi, S., Nakamura, K., Tanaka, M., Oki, E., Takayanagi, R., & Oda, Y. (2015). Molecular characteristics of colorectal neuroendocrine carcinoma; Similarities with adenocarcinoma rather than neuroendocrine tumor. *Human Pathology*, 46(12), 1890-1900. <https://doi.org/10.1016/j.humpath.2015.08.006>
- Uccella, S., Sessa, F., & La Rosa, S. (2015). Diagnostic approach to neuroendocrine neoplasms of the gastrointestinal tract and pancreas. *Turk Patoloji Dergisi*, 31, 113-127. <https://doi.org/10.5146/tjpath.2015.01319>
- Walker, M. J. (1987). Rare tumors of the colon and rectum. *Problems in General Surgery*, 4(1), 141-153. <https://doi.org/10.5772/56937>
- Wiedenmann, B., Franke, W. W., Kuhn, C., Moll, R., & Gould, V. E. (1986). *Synaptophysin: A marker protein for neuroendocrine cells and neoplasms*. 83(18), 3500-3504.

DAFTAR LAMPIRAN

Lampiran 1. Daftar Sampel Penelitian

Lampiran 2. Surat Rekomendasi Kelayakan Etik

Lampiran 1. Daftar Sampel Penelitian

1. Tabel Ekpresi Chromogranin A/Synaptophysin Positif/Positif

N0	Pola Pertumbuhan	Sito morfologi	Chromogranin A	Synaptophysin	Mitosis (/10LPB)	Ki67 (%)	Diagnosa
1	Insular	Non Klasik	Positif	Positif	< 2	< 3	NET G1
2	Trabekular	Large Cell	Positif	Positif	> 20	> 20	LCNEC
3	Glandular	Large Cell	Positif	Positif	> 20	> 20	LCNEC
4	Glandular	Klasik	Positif	Positif	> 20	> 20	NET G3
5	Glandular	Large Cell	Positif	Positif	> 20	> 20	LCNEC
6	Berdiferensiasi buruk	Large Cell	Positif	Positif	> 20	> 20	LCNEC
7	Berdiferensiasi buruk	Large Cell	Positif	Positif	> 20	> 20	LCNEC
8	Berdiferensiasi buruk	Klasik	Positif	Positif	2-20	3-20	NET G2

2. Tabel Ekpresi Chromogranin A/ Synaptophysin Positif/Negatif

N0	Pola Pertumbuhan	Sito morfologi	Chromogranin A	Synaptophysin	Mitosis (/10LPB)	Ki67 (%)	Diagnosa
1	Insular	Large Cell	Positif	Negatif	>20	>20	Belum spesifik

3. Tabel Ekpresi Chromogranin A/ Synaptophysin Negatif/Negatif

NO	Pola Pertumbuhan	Sito morfologi	Mitosis (/10LPB)	Chromogranin A	Synaptophysin	Diagnosa
1	Insular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
2	Insular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
3	Insular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
4	Insular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
5	Insular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
6	Insular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
7	Insular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
8	Insular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
9	Insular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
10	Insular	Large Cell	<2	Negatif	Negatif	Adenokarsinoma High Grade
11	Insular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
12	Insular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
13	Insular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
14	Insular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
15	Insular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
16	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
17	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
18	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
19	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
20	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
21	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
22	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma

23						High Grade
24	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
25	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
26	Insular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
27	Trabekular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
28	Trabekular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
29	Trabekular	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
30	Trabekular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
31	Trabekular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
32	Trabekular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
33	Trabekular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
34	Trabekular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
35	Trabekular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
36	Glandular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
37	Glandular	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
38	Glandular	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
39	Glandular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
40	Glandular	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
41	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
42	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
43	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
44	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
45	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
46	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
47	Berdiferensiasi buruk	Non Klasik	<2	Negatif	Negatif	Adenokarsinoma High Grade

48	Berdiferensiasi buruk	Non Klasik	<2	Negatif	Negatif	Adenokarsinoma High Grade
49	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
50	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
51	Berdiferensiasi buruk	Non Klasik	3-20	Negatif	Negatif	Adenokarsinoma High Grade
52	Berdiferensiasi buruk	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
53	Berdiferensiasi buruk	Non Klasik	>20	Negatif	Negatif	Adenokarsinoma High Grade
54	Berdiferensiasi buruk	Non Klasik	<2	Negatif	Negatif	Adenokarsinoma High Grade
55	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
56	Berdiferensiasi buruk	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
57	Berdiferensiasi buruk	Large Cell	3-20	Negatif	Negatif	Adenokarsinoma High Grade
58	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
59	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
60	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
61	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade
62	Berdiferensiasi buruk	Large Cell	>20	Negatif	Negatif	Adenokarsinoma High Grade

Lampiran 2. Surat Rekomendasi Kelayakan Etik



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
 UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
 KOMITE ETIK PENELITIAN KESEHATAN
 RSPTN UNIVERSITAS HASANUDDIN
 RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
 Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
 JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari.,MMed,PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 410/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 10 Agustus 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080341	No Sponsor Protokol	
Peneliti Utama	dr. Gusti Deasy Wilda Ariani	Sponsor	
Judul Peneliti	EKSPRESI CHROMOGRANIN A DAN SYNAPTOPHYSIN DALAM MENDETEKSI NEUROENDOKRIN NEOPLASMA PADA ADENOKARSINOMA KOLOREKTAL HIGH GRADE		
No Versi Protokol	1	Tanggal Versi	3 Agustus 2020
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium PA Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 10 Agustus 2020 sampai 10 Agustus 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

DAFTAR TABEL

Tabel 1	Klasifikasi dan kriteria grading untuk neoplasma neuroendokrin dari traktus gastrointestinal dan hepatopankreatobilier	13
Tabel 2	Klasifikasi TNM untuk tumor neuroendokrin pada organ kolorektal	14
Tabel 3	Stage tumor neuroendokrin pada kolon dan rektum	15
Tabel 4	Kriteria ekspresi chromogranin A dan synaptophysin	41
Tabel 5	Karakteristik Umum Sampel	49
Tabel 6	Karakteristik Sampel NEN	51
Tabel 7	NEN Berdasarkan Jenis kelamin, usia, gejala klinik, lokasi, ukuran tumor, pola pertumbuhan, dan sitomorfologi	53

DAFTAR GAMBAR

Gambar 1	Anatomi kolorektal	7
Gambar 2	Histologi kolorektal yang menunjukkan empat lapisan dinding usus besar	9
Gambar 3	Pola pertumbuhan tumor pada NEN	16
Gambar 4	Sitomorfologi NEN Klasik	17
Gambar 5	Morfologi inti pada NEN	17
Gambar 6	Morfologi sitoplasma pada NEN	18
Gambar 7	Gambaran morfologi pada NEC	18
Gambar 8	Gambaran latar belakang pada NEN	19
Gambar 9	Patofisiologi tumor neuroendokrin	21
Gambar 10	Granulogenesis dan regulasi sekresi Chromogranin A	22
Gambar 11	Chromogranin A berperan dalam beragam interaksi Fisiologis	27
Gambar 12	Pulasan Chromogranin A pada sel tumor neuroendokrin	28
Gambar 13	Pulasan Synaptophysin pada sel tumor neuroendokrin	30
Gambar 14	Pola pertumbuhan tumor pada NEN dari pewarnaan HE	45
Gambar 15	Sitomorfologi NEN dari pewarnaan HE	46
Gambar 16	Persentase intensitas sel dengan ekspresi chromogranin A	47
Gambar 17	Ekspresi Chromogranin A (+) / Synaptophysin (+)	48
Gambar 18	Ekspresi Chromogranin A (+) / Synaptophysin (-)	48
Gambar 19	Ekspresi Chromogranin A (-) / Synaptophysin (-)	48

DAFTAR ARTI LAMBANG DAN SINGKATAN

CgA	: Chromogranin A
GI	: Gastrointestinal
HE	: Hematoksilin–Eosin
LCNEC	: Large Cell Neuroendocrine Carcinoma
MINEN	: Mixed neuroendocrine – non-neuroendocrine neoplasm
NE	: Neuroendokrin
NEC	: Neuroendocrine Carcinoma
NEN	: Neuroendokrin Neoplasma
NET	: Neuroendokrin Tumor
NSE	: Neuron Specific Enolase
RS Unhas	: RS. Universitas Hasanuddin
RSWS	: RS. Dr. Wahidin Sudirohusodo
SDPM	: Sentra Diagnostik Patologia Makassar
SEER	: Surveillance Epidemiology and End Results
SCNEC	: Small cell Neuroendocrine Carcinoma
SSAS	: somatostatin analog
SYP	: Synaptophysin